Form 4: Exelixis Director Receives Equity Grant

Director Jack L. Wyszomierski was granted 8,367 restricted stock units as part of the Exelixis, Inc. 2017 Equity Incentive Plan.

Summary

• Director Jack L. Wyszomierski acquired 8,367 restricted stock units (RSUs) on May 27, 2026.
• The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• Each RSU represents the economic equivalent of one share of common stock.
• The total beneficial ownership following the transaction is 288,309 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the Reporting Person's continuous service through May 27, 2027.

Future Outlook

The RSUs are scheduled to vest 100% on May 27, 2027, contingent upon the director's continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for mid-to-large cap biotechnology firms.
• The one-year cliff vesting schedule is a common retention mechanism for board members.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• Vesting of the 8,367 RSUs on May 27, 2027.

Key Dates

Keywords

Exelixis, EXEL, Director, Equity, RSU, Insider Transaction